间充质干细胞来源的外泌体治疗早产儿并发症的研究进展  

Study progress of exosomes derived from mesenchymal stem cells in the treatment of complications related to preterm infants

作　　者：陈浩明 郝庆飞[1] 程秀永[1] Chen Haoming;Hao Qingfei;Cheng Xiuyong(Department of Neonatology,First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院新生儿科,郑州450052

出　　处：《中华实用儿科临床杂志》2021年第21期1673-1676,共4页Chinese Journal of Applied Clinical Pediatrics

摘　　要：尽管围生医学和新生儿医学已经取得了较大进展,但早产儿相关并发症的发病率及死亡率仍较高。目前支气管肺发育不良、脑损伤、坏死性小肠结肠炎、早产儿视网膜病变等早产儿相关并发症的防治仍是临床难点。在实验水平上,基于间充质干细胞的再生医学已经被证明是治疗这些疾病有前景的方法,但是其存在致瘤性、免疫排斥等潜在的风险。研究表明,外泌体是间充质干细胞发挥作用的关键介质。因此,近年来,外泌体已经成为治疗早产儿相关并发症的新选择。现对间充质干细胞来源的外泌体治疗早产儿并发症的研究进展作一综述。Although great progress has been made in perinatal and neonatal medicine,the morbidity and mortality of premature complications remain high.At present,the prevention and treatment of preterm infants with broncho-pulmonary dysplasia,brain injury,necrotizing enterocolitis,retinopathy of prematurity and other complications are cha-llenging.Experimental evidences have shown that regenerative medicine based on mesenchymal stem cells is a promising therapeutic strategy for premature complications,although it has potential risks like tumorigenicity and immune rejection.Exosomes are the key mediators of mesenchymal stem cells,which have been a promising method for the treatment of premature complications.This study aims to review the research progress of exosomes derived from mesenchymal stem cells in the treatment of premature complications.

关 键 词：外泌体 间充质干细胞 早产 支气管肺发育不良 脑损伤 坏死性小肠结肠炎 早产儿视网膜病变 

分 类 号：R722.6[医药卫生—儿科]